EBS

4.59

2.23% 0.10

Dopo l'orario di chiusura: 4.57 -0.02 -0.44%

Emergent Biosolutions Inc (EBS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$4.49

Aprire:

$4.5

Volume 24 ore:

1.09M

Relative Volume:

1.11

Capitalizzazione di mercato:

$235.34M

Reddito:

$676.80M

Utile/perdita netta:

$-8.60M

Rapporto P/E:

-16.22

EPS:

-0.2829

Flusso di cassa netto:

$135.40M

1 W Prestazione:

-5.17%

1M Prestazione:

-38.80%

6M Prestazione:

-57.62%

1 anno Prestazione:

-47.96%

Intervallo 1D:

$4.45

$4.67

Intervallo di 1 settimana:

$4.36

$4.73

Portata 52W:

$4.36

$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Nome

Emergent Biosolutions Inc

Settore

Healthcare (1080)

Industria

Drug Manufacturers - Specialty & Generic (87)

Telefono

240-631-3200

Indirizzo

300 PROFESSIONAL DR, GAITHERSBURG, MD

Dipendente

900

Cinguettio

@emergentbiosolu

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

EBS's Discussions on Twitter

Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EBS Emergent Biosolutions Inc	4.59	233.29M	676.80M	-8.60M	135.40M	-0.2829
TAK Takeda Pharmaceutical Co Adr	17.63	55.60B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.77	42.81B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.70	43.16B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.79	30.39B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	499.73	21.95B	3.17B	1.29B	1.01B	27.09

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-30	Iniziato	H.C. Wainwright	Buy
2024-08-22	Iniziato	Rodman & Renshaw	Buy
2024-03-07	Aggiornamento	The Benchmark Company	Hold → Buy
2023-11-20	Ripresa	JP Morgan	Underweight
2023-08-29	Downgrade	The Benchmark Company	Buy → Hold
2023-04-10	Aggiornamento	The Benchmark Company	Hold → Buy
2023-03-17	Downgrade	JP Morgan	Neutral → Underweight
2022-11-10	Downgrade	The Benchmark Company	Buy → Hold
2022-04-29	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2022-01-20	Aggiornamento	The Benchmark Company	Hold → Buy
2021-11-08	Downgrade	The Benchmark Company	Buy → Hold
2021-05-05	Downgrade	Argus	Buy → Hold
2021-04-07	Iniziato	The Benchmark Company	Buy
2021-02-24	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2021-02-19	Downgrade	Chardan Capital Markets	Buy → Neutral
2021-01-08	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-09-14	Ripresa	JP Morgan	Neutral
2020-07-31	Reiterato	Chardan Capital Markets	Buy
2019-09-12	Iniziato	Guggenheim	Buy
2019-09-04	Aggiornamento	Wells Fargo	Market Perform → Outperform
2018-11-02	Aggiornamento	Goldman	Neutral → Buy
2018-08-03	Reiterato	Chardan Capital Markets	Buy
2018-06-13	Iniziato	Argus	Buy
2018-04-25	Downgrade	Wells Fargo	Outperform → Market Perform
2018-01-24	Iniziato	Goldman	Neutral
2018-01-16	Reiterato	Chardan Capital Markets	Buy
2016-06-28	Reiterato	Singular Research	Buy
2016-04-15	Iniziato	Chardan Capital Markets	Buy
2016-03-28	Iniziato	Singular Research	Buy
2016-02-19	Iniziato	Wells Fargo	Outperform
2014-05-15	Iniziato	Summer Street Research	Buy
2011-05-31	Reiterato	WBB Securities	Strong Buy
2011-01-10	Reiterato	Wedbush	Outperform
2010-11-05	Reiterato	Wedbush	Outperform
2010-08-18	Aggiornamento	WBB Securities	Buy → Strong Buy
2010-08-06	Reiterato	Caris & Company	Buy

Mostra tutto

Emergent Biosolutions Inc Borsa (EBS) Ultime notizie

Aug 16, 2026

Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts - marketbeat.com

Aug 16, 2026

Aug 15, 2026

Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

Aug 15, 2026

Aug 14, 2026

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G - Stock Titan

Aug 14, 2026

Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS - MarketBeat

Aug 14, 2026

Aug 13, 2026

Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire

Aug 13, 2026

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research - marketbeat.com

Aug 13, 2026

Aug 12, 2026

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript - AOL.com

Aug 12, 2026

EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS) - Business Wire

Aug 12, 2026

Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings - Stock Titan

Aug 12, 2026

Aug 11, 2026

Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades - finance.biggo.com

Aug 11, 2026

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions - PR Newswire

Aug 11, 2026

EMERGENT BIOSOLUTIONS INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $10 FROM $12 - webull.com

Aug 11, 2026

Why Did TTD, PZZA, EBS Stocks Plummet To 52 Week Lows? - Stocktwits

Aug 11, 2026

Aug 10, 2026

Emergent BioSolutions cuts FY2026 revenue forec... - Pluang

Aug 10, 2026

Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) - PR Newswire

Aug 10, 2026

H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Aug 10, 2026

H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook - Investing.com Nigeria

Aug 10, 2026

Emergent Biosolutions (NYSE:EBS) Given New $10.00 Price Target at HC Wainwright - marketbeat.com

Aug 10, 2026

EBS Maintained by HC Wainwright & Co. -- Price Target Lowered to $10 - GuruFocus

Aug 10, 2026

Aug 09, 2026